香港联交所最新资料显示，10月2日，主席兼执行董事蔡东晨增持石药集团(01093)600万股，每股作价 为9.6383港元，总金额为5782.98万港元。增持后最新持股数目约为28.34亿股，最新持股比例为 24.59%。 ...

智通财经APP获悉，香港联交所最新资料显示，10月2日，主席兼执行董事蔡东晨增持石药集团 (01093)600万股，每股作价为9.6383港元，总金额为5782.98万港元。增持后最新持股数目约为28.34亿 股，最新持股比例为24.59%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 石藥集團有限公司 | | | 呈交日期: | 2025年10月2日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01093 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 11,521,951,732 | | 0 | | 11,521,951,732 | | 增加 / 減少 (-) | | | 50 ...

Major Events - Jinye International Group (08549) plans to issue 100 million shares from September 30 to October 6 [1] - Zhida Technology (02650) intends to globally issue 5.9789 million shares, expecting to list on October 10 [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval for SYH2070 injection (double-stranded small interfering RNA drug) in China [1] - Mixue Group (02097) plans to invest in a fresh beer product company to seize opportunities in the fresh beer industry [1] - Shangshan Gold (01939) proposes a placement at a discount of approximately 19.88%, aiming to raise about HKD 245.8 million [1] - GC Construction (01489) sees a change in controlling interest with a buyout offer at a discount of about 45.91%, resuming trading on October 2 [1] - Times Financial Services Group (00510) major shareholder plans to sell some shares, resuming trading on October 2 [1] - Huajian Medical (01931) confidentially submitted an F-1 registration statement for a dual listing in the U.S. [1] - Ding Shi Capital (00804) intends to acquire 100% equity of a distressed asset disposal business, actively entering the distressed asset market [1] - Chuangmeng Tiandi (01119) plans to issue a total of 236 million shares [1] - Zhaogang Group-W (06676) intends to conduct a share buyback [1] - Daren International (01957) is exploring the possibility of acquiring up to 100 bitcoins [1] - Sihuan Pharmaceutical (00460) received approval from the National Medical Products Administration for its self-developed L-carnosine composite solution water light needle "Frozen Beauty" [1] Bonds and Notes - Minmetals Resources (01208) plans to issue USD 500 million zero-coupon convertible bonds maturing in 2030 [2] Share Buybacks - Tencent Holdings (00700) repurchased approximately 832,000 shares for about HKD 551 million on September 30 [2] - Midea Group (00300) spent approximately CNY 146 million to repurchase 2.0015 million A-shares on September 30 [2] - Anta Sports (02020) repurchased approximately 1.000 million shares for about HKD 99.87 million on September 30 [2] - SF Holding (06936) repurchased approximately 937,600 A-shares for about CNY 37.78 million on September 30 [2] - HSBC Holdings (00005) repurchased approximately 2.1133 million shares for about GBP 22.07 million on September 29 [2] Operating Performance - BYD Company (01211) reported approximately 3.2601 million new energy vehicle sales in the first nine months, a year-on-year increase of 18.64% [2] - Geely Automobile (00175) reported total vehicle sales of 273,100 units in September, a year-on-year increase of approximately 35% [2] - Great Wall Motors (02333) reported total vehicle sales of approximately 133,600 units in September, a year-on-year increase of 23.29% [2] - NIO Inc. (09866) delivered 34,749 vehicles in September, setting a new monthly record with a year-on-year increase of 64.1% [2] - Li Auto (02015) delivered 33,951 new vehicles in September [2]

格隆汇9月30日丨石药集团(01093.HK)公告，于2025年9月30日，公司间接非全资附属公司石药创新董事 会已批准于联交所主板的H股建议上市。预期紧随H股建议上市完成后，石药创新将仍为公司间接附属 公司。现时预期H股建议上市将涉及透过石药创新新H股于联交所主板首次公开发售进行提呈发售以供 认购，占紧随H股建议上市完成后石药创新经扩大已发行股本不超过10%(假设超额配股权未获行使)。 ...

智通财经APP讯，石药集团(01093)公布，于2025年9月30日，公司间接非全资附属公司石药创新董事会 已批准于联交所主板的H股建议上市。预期紧随H股建议上市完成后，石药创新将仍为公司的间接附属 公司。 假设紧随H股建议上市完成后石药创新经扩大已发行股本的10%将获发行及超额配股权获悉数行使，石 药创新根据H股建议上市发行及配发发售股份，将导致公司于石药创新的股权百分比减少约8.46%，而 紧随H股建议上市完成后，公司将持有石药创新约66.20%股权。 ...

石药集团(01093)公布，于2025年9月30日，公司间接非全资附属公司石药创新董事会已批准于联交所主 板的H股建议上市。预期紧随H股建议上市完成后，石药创新将仍为公司的间接附属公司。 假设紧随H股建议上市完成后石药创新经扩大已发行股本的10%将获发行及超额配股权获悉数行使，石 药创新根据H股建议上市发行及配发发售股份，将导致公司于石药创新的股权百分比减少约8.46%，而 紧随H股建议上市完成后，公司将持有石药创新约66.20%股权。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 須予披露交易 石藥創新H股建議上市所致之視作出售於石藥創新之股權 H股建議上市 董事會宣佈，於2025年9月30日，本公司間接非全資附屬公司石藥創新董事會已批准於聯 交所主板的H股建議上市。預期緊隨H股建議上市完成後，石藥創新將仍為本公司之間接 附屬公司。 現時預期H股建議上市將涉及透過石藥創新之新H股於聯交所主板首次公開發售進行提呈 發 售 以 供 認 購 ， 佔 緊 隨 H 股 建 議 上 市 完 成 後 石 藥 創 新 之 經 擴 大 已 發 行 股 本 不 超 過 10 % （ 假設超額配股權未獲行使 ）。 上市規則的涵義 石 藥創 新 根 據H 股 建 議 上 市發 行 及 配發 發 售 股份 將 導 致本 公 司 於石 藥 創 新之 股 權 ...

Core Viewpoint - The announcement highlights that the company has received approval from the National Medical Products Administration of China for its self-developed Class 1 chemical new drug SYH2070 injection, a dual-strand small interfering RNA (siRNA) drug, to conduct clinical trials in China [1] Group 1: Product Details - SYH2070 is designed for liver-targeted delivery of siRNA through the conjugation of N-acetylgalactosamine (GalNAc) and aims to target angiopoietin-like protein 3 (ANGPTL3) to effectively lower ANGPTL3 levels [1] - The product utilizes optimized sequences and chemical modifications to achieve a more prolonged gene silencing effect, positioning it as a long-acting siRNA drug suitable for treating hypertriglyceridemia or mixed hyperlipidemia [1] - It has the potential to effectively reduce the risk of elevated residual cholesterol levels [1] Group 2: Clinical Development Value - Preclinical studies indicate that SYH2070 demonstrates superior drug activity and efficacy duration compared to similar siRNA products, showcasing differentiated advantages such as lasting drug effects, good safety profile, and high patient compliance [1] - The product holds significant clinical development value due to its promising characteristics [1]

Core Viewpoint - The approval of SYH2070 injection, a novel siRNA drug developed by the company, marks a significant advancement in targeted therapies for hypertriglyceridemia and mixed dyslipidemia, with potential benefits in reducing residual cholesterol levels [1] Group 1: Product Development - The drug SYH2070 is a chemically modified siRNA that targets ANGPTL3 through subcutaneous administration, utilizing GalNAc for liver-targeted delivery [1] - Preclinical studies indicate that SYH2070 demonstrates superior drug activity and prolonged efficacy compared to similar siRNA products, highlighting its differentiated advantages in terms of sustained drug action and safety [1] Group 2: Clinical Implications - The drug is expected to provide a long-lasting effect in lowering ANGPTL3 levels, which is crucial for treating conditions like hypertriglyceridemia and mixed dyslipidemia [1] - The potential for high patient compliance is noted, which could enhance the drug's market acceptance and therapeutic impact [1]